-
Attention Biotech Investors: Mark Your Calendar For These August PDUFA Dates
Wednesday, August 1, 2018 - 7:38am | 1657Read More...Biotech stocks had a fairly decent run up in July after a nearly flat performance in June. The iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB) is up about 5 percent. As the earnings season kicks into high gear and amid several other catalysts, August is likely to be an action-packed...
-
Priority Review For Tetraphase's Eravacycline A 'Key Positive,' Analyst Says
Wednesday, February 28, 2018 - 3:48pm | 302Read More...Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH) announced Tuesday that the U.S. Food and Drug Administration accepted a New Drug Application for eravacycline, an antibiotic for complicated intra-abdominal infection, for priority review. Traders initially reacted positively, and so did analysts. The...
-
Tetraphase Pharma Shares Plunge After Antibiotic Fails Late-Stage Trial
Wednesday, February 14, 2018 - 12:55pm | 475Read More...Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH)'s Ignite3 trial evaluating the company's lead drug candidate eravacycline for treating complicated urinary tract infections, or cUTIs, failed to ace a late-stage trial. At last check, the shares were plunging nearly 61 percent to $2.12....
-
Is Tetraphase Pharmaceuticals A Buyout Candidate? Brean Capital Thinks So
Friday, March 6, 2015 - 11:46am | 215Read More...In a report published Friday, Brean Capital analyst Jonathan Aschoff said that that Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH) is a "prime takeout candidate" as the company continues to target NDA submission for eravacycline for both indications (cUTI and cIAI) by the end of 2015...
